FDA hosts a public meeting next month aimed at exploring ways to expand access to nonprescription medications.
U.S. Senator Rick Scott (R-FL) urges FDA and other federal health agencies to review and tighten oversight of clinical trials and drug approvals involving Chinese-linked entities, citing potential national security and patient safety risks.
FDA hosts a public meeting next month aimed at exploring ways to expand access to nonprescription medications.
U.S. Senator Rick Scott (R-FL) urges FDA and other federal health agencies to review and tighten oversight of clinical trials and drug approvals involving Chinese-linked entities, citing potential national security and patient safety risks.
FDA approves Bristol Myers Squibb’s Opdivo (nivolumab) for use with doxorubicin, vinblastine, and dacarbazine for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma.
FDA is announcing a 6/12 public hearing to gather input on its Commissioner’s National Priority Voucher Pilot Program.
